Infinity licenses Intellikine's PI3K inhibitors for up to $488 million
This article was originally published in Scrip
Executive Summary
Infinity Pharmaceuticals, a US drug discovery and development company specialising in cancer and related conditions, is paying up to $488.5 million for global development and commercialisation rights to a portfolio of PI3K inhibitors assembled by fellow US firm Intellikine.